Stockreport

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an i [Read more]